Skip to navigation

Myelodysplastic Syndromes

Indications: Myelodysplastic Syndromes
Drug Candidate: Mocetinostat
 

Mirati Therapeutics is enrolling a Phase 2 study evaluating the effects of mocetinostat as a treatment for patients with intermediate- and high-risk myelodysplastic syndromes (MDS) in combination with current front-line therapy azacitidine. This study will evaluate mocetinostat in patients that previously received treatment with hypomethylating agents such as azacitidine (marketed as Vidaza®), in patients that have not received prior treatment with this class of anti-cancer agents, and in patients that are receiving azacitidine for the first time.


Vidaza® is a registered trademark of Celgene Corp.

Find an Active Trial